GMGerhard Moser

Gerhard Moser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gerhard Moser has a total of 88 co-authors. Here are the top co-authors by number of shared publications:

  • Gerd Rasp

    Universitätsklinik für Hals-Nasen-Ohrenheilkunde der Paracelsus Medizinischen Privatuniversität Salzburg, Österreich

    4 shared publications
  • Alexander Egle

    Cancer Research Laboratory of the 3rd Medical University Department for Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Paracelsus Medical University, Salzburg, Austria

    3 shared publications
  • Lajos Patonay

    3 shared publications
  • Miklós Tóth

    Department of Otorhinolaryngology and †Department of Dermatology, Paracelsus Medical University, Salzburg, Austria

    3 shared publications
  • Sebastian Roesch

    Department of Otorhinolaryngology, Head and Neck Surgery, Paracelsus Medical University, Salzburg, Austria

    3 shared publications
  • Teresa Magnes

    Oncologic Center, Department of Internal Medicine III with Haematology, Medical Oncology, Haemostaseology, Infectiology and Rheumatology, Paracelsus Medical University, 5020 Salzburg, Austria

    3 shared publications

Latest Publications

  • Chirurgisch-interventionelle Aspekte

    by Gerhard Moser, Peter Kress, Christian Zauner, Dietmar Thurnher


  • Open Access

    Prognostic score in patients with recurrent or metastatic carcinoma of the head and neck treated with cetuximab and chemotherapy

    by Teresa Magnes, Thomas Melchardt, Lukas Weiss, Christof Mittermair, Daniel Neureiter, Eckhard Klieser, Simon Gampenrieder, Gerhard Moser, Alexander Gaggl, Richard Greil, et al.

    Despite modern treatment approaches, survival of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) remains low and it is difficult to identify patients who derive optimal benefit from treatment. We therefore analyzed which commonly available laboratory and clinical parameters may help improve the prognostication in this patient group. This retrospective monocenter analysis includes 128 patients with recurrent or metastatic SCCHN treated with cetuximab alone or in combination with polychemotherapy as first line therapy. Factors with independent prognostic power in the multivariate analysis were used to build up a score separating patient groups with different survival. Patients had a median age of 61 years and 103 patients were treated with polychemotherapy plus cetuximab. An ECOG score above 1, high CRP and leukocyte levels, less intensive treatment and a time below 12 months from primary diagnosis to relapse remained as independent negative prognostic factors in multivariate analysis. Patients with 0 to 1 risk factors had a median OS of 13.6 months compared to a median OS of less than one month for patients 4 to 5 risk factors (p<0.001). This study identifies 5 clinical and serum values that influence survival of patients with recurrent or metastatic SCCHN treated with cetuximab. By combining these factors to create a score for OS, it is possible to distinguish a group of patients with significantly improved survival and define those most likely to have no benefit from cetuximab treatment.


  • Open Access

    Anti-Hu Antibody Associated Paraneoplastic Cerebellar Degeneration in Head and Neck Cancer

    by Florian Huemer, Thomas Melchardt, Wolfgang Tränkenschuh, Daniel Neureiter, Gerhard Moser, Teresa Magnes, Lukas Weiss, Alexander Schlattau, Clemens Hufnagl, Gerda Ricken, et al.

    Paraneoplastic syndromes are most frequently associated with small cell lung carcinoma, hematologic and gynecologic malignancies while reports in head and neck cancer are rare. We present the case of a 60-year old female patient who developed paraneoplastic cerebellar degeneration upon locoregional recurrence of a poorly differentiated spindle cell carcinoma of the nasal cavity and paranasal sinus. The neurological symptoms, especially ataxia, stabilized after resection of tumor recurrence and concomitant chemoradiotherapy whereas anti-Hu-antibodies remained positive. Despite the unfavorable prognosis of paraneoplastic neurological disorders associated with onconeural antibodies, the patient achieved long-standing stabilization of neurological symptoms. We report the first patient with anti-Hu antibodies and paraneoplastic cerebellar degeneration associated with a spindle cell carcinoma of the head and neck. We recommend that evaluation of neurological symptoms in patients with this tumor entity should also include paraneoplastic syndromes as differential diagnoses and suggest early extensive screening for onconeural antibodies.


  • Open Access

    CYP39A1 polymorphism is associated with toxicity during intensive induction chemotherapy in patients with advanced head and neck cancer

    by Thomas Melchardt, Clemens Hufnagl, Teresa Magnes, Lukas Weiss, Georg Hutarew, Daniel Neureiter, Alexander Schlattau, Gerhard Moser, Alexander Gaggl, Wolfgang Tränkenschuh, et al.

    Induction chemotherapy incorporating docetaxel, cisplatin and 5- fluorouracil before radiotherapy may improve the outcome of patients with advanced head and neck cancer. Nevertheless, the addition of docetaxel increases hematological toxicity and infectious complications. Therefore, genetic markers predicting toxicity and efficacy of this treatment regimen may help to identify patients, who would have the most benefit from this intensive treatment. A cohort of 78 patients with advanced head and neck cancer treated with induction chemotherapy was assessed for clinical outcome and toxicity during treatment with curative intention. Genetic polymorphisms primary associated with treatment efficacy (ERCC2-rs13181, rs1799793, ERCC1-rs3212986, rs11615, XRCC1-rs25487) or with docetaxel caused toxicity (CYP39A1-rs7761731, SLCO1B3-rs11045585) were evaluated in all patients. The results of these analyses were correlated with the clinical outcome of the patients (loco regional control, progression free survival, overall survival) and treatment related toxicity during induction chemotherapy. Median progression free survival and overall survival was 20 and 31 months in an intention to treat analysis, respectively. Overall response rate to induction chemotherapy was high with 78.1 % of all patients. None of the polymorphisms tested was associated with the clinical outcome of the patients. Genotype A of the CYP39A1 rs7761731 polymorphism was associated with a higher incidence of leucopenia and infections or death during induction chemotherapy. Intensive induction chemotherapy results in a high response rate in the majority of patients. None of the polymorphisms tested was associated with the clinical outcome of the patients. The CYP39A1 polymorphism rs7761731 may help to identify patients at high risk for treatment related toxicity.


  • Ectopic Apocrine Glands as a Predisposing Factor for Postinflammatory Medial Meatal Fibrosis

    by Gerhard Moser, Michael Emberger, Miklós Tóth, Sebastian Roesch, Gerd Rasp, Martin Laimer

    Objective To illuminate pathophysiologic processes in postinflammatory medial meatal fibrosis (PMMF), a rare otologic disease of unknown etiology, which is defined by a progressive, obliterating fibrosis that affects the osseous part of the external auditory canal (EAC) exclusively. Study Design Retrospective clinical and histopathologic study. Setting Tertiary referral center. Patients Eleven patients (4 female and 7 male subjects) who underwent surgery of the bony EAC due to PMMF (13 ears operated). Methods Histologic and immunohistochemical assessment of tissue specimens obtained during surgical excision. Main Outcome Measure Detection of ectopic apocrine glands and concomitant inflammatory infiltrate within tissue harvested from the osseous EAC. Results Additionally to expected histologic findings, such as excessive fibrosis and a chronic inflammatory infiltrate, ectopic spread of apocrine glands was consistently detected in all of our patients. Conclusion Based on our findings, we suggest that an ectopic occurrence of adnexal structures within the bony EAC may predispose susceptible individuals to the development of PMMF. To avoid postoperative recurrence due to iatrogenic spread of cutaneous adnexal structures during surgery, the split-thickness skin graft should not exceed a thickness of 0.4 mm.


  • Exenteratio Orbitae – chirurgische und rekonstruktive Strategien

    by Martin Emesz, Gerhard Oberascher, Gerhard Moser, Eva Maria Arlt, Eva Maria Krall, Max Rasp, Alexander Bachernegg


  • Anatomic Parameters of the Long Process of Incus for Stapes Surgery

    by Miklós Tóth, Gerhard Moser, Sebastian Rösch, Gernot Grabmair, Gerd Rasp

    Hypothesis The purpose of this study is to offer new anatomic data about the long process of incus (LPI) for stapes surgery. Background Anatomic study of 50 human macerated incudes to measure different parameters of cross sections of the LPI. Methods Step-by-step cutting of the LPI perpendicular to its axis starting from its free end next to the lenticular process. The layer thickness was 0.5 mm. The cutting surfaces were documented with Canon EOS 20D camera, and a standard software tool (MATLAB) was used for automated statistical analysis. Results The LPI had a maximum diameter of 1.15 mm and a minimum diameter of 0.52 mm at the level of 1.5 mm far from the tip of the long process, which is the most common site for stapes prosthesis attachment. Concerning each cross section, having a long and a short diameter, the average long diameter is 0.9011 mm, and the short diameter is 0.6507 mm. Conclusion Our anatomic study revealed wide variations of diameters and shape of the LPI. Best possible crimping of stapes prosthesis depends not only on the shape and diameters of the LPI but also on the vertical surface of the LPI as well. To prevent incus necrosis due to compression of the feeding blood vessels, the maximum contact surface of the loop of stapes prosthesis should be about 1.9 mm in length.